April 27, 2017 News Tags:

For immediate release

Nucleus Biologics Announces New Vice President of Sales

Media supplement innovator adds cell biology industry veteran to expand market footprint and meet needs of company’s growing customer base in research, biotech, and pharma

SAN DIEGO – APRIL 27, 2017 – Nucleus Biologics, a cell culture products supplier to the life science research, biotechnology and pharmaceutical industries, is announcing the addition of Daniel Schroen as Vice President of Sales. Dr. Schroen will oversee expansion of markets in key areas such as bioprocessing, pharmaceuticals, drug discovery and academic research. In addition, he will focus on serving the high-quality serum supplementation needs of large scale biopharma manufacturers and contract manufacturing organizations (CMOs) throughout North America.

Dan Schroen, Vice President of SalesDr. Schroen has been in the cell biology field since 1989, first as a research scientist, and then in progressively senior business roles upon transitioning to the industrial sector in 1998. He most recently served as Vice President, Sales and Marketing for Cell Applications, Inc., where he also helped grow the distributor base and form strategic partnerships. Before that, he gained business development and commercialization skills as Marketing Director and Product Manager at various divisions of now Thermo Fisher Scientific and DuPont. He holds a PhD, with emphasis in cell biology and immunology, from Illinois State University, where his work on immune cell behavior earned the Clarence W. Sorensen Distinguished Ph.D. Dissertation Award, and completed postdoctoral fellowships at Dartmouth Medical School and the University of Massachusetts.

“With the recent advancements in cell biology, I was drawn to work with Nucleus Biologics because of its commitment to providing the high-quality sera needed today in research, academia, bioprocessing, and biotech organizations. Nucleus Biologics’ focus on sourcing FBS through exclusive agreements with suppliers in preferred countries of origin, is changing the paradigm for customers and allowing access to high quality, traceable serum at fixed prices and assured supply,” said Schroen. “I look forward to being a part of Nucleus Biologics’ continued growth.”

With FBS being a critical food for cells used in ground-breaking research and drug development, Nucleus Biologics offers a transparent, consistent, and proven supply chain that helps to eliminate variability and ensure highly-characterized, low-viral serum and more consistent scientific results. The company re-defines serum with its stringent testing policy (78 tests in all) and ensures stable supply and pricing via an exclusive agreement with Australian Agricultural Company (AACo) – the largest cattle company in a country known to be BSE- and FMD-free – as its source for raw material.

“We are very excited to welcome Dan to our team. His experience as a scientist is invaluable in understanding the frustrations and unique needs of all of our customers- whether high volume bioprocessing or basic research. As we build our team we are adding members who embody our values and understand how innovation can happen even in mature markets like FBS,” said Nucleus Biologics Chief Executive Officer David Sheehan. “Dan will accelerate the early commercial success we are seeing with our first product and position us well for the launch of our Xeno free product.”

Schroen along with the Nucleus Biologics team will be exhibiting at the AAPS National Biotechnology Conference May 1 – 3 in San Diego.

About Nucleus Biologics

Nucleus Biologics is a San Diego-based supplier of premium cell culture products for biotech and pharmaceutical companies throughout North America. The company feeds scientific breakthrough by partnering with the source and redesigning the traditional cell culture products supply chain for greater transparency and superior quality. Nucleus Biologics’ premier product offering is an exceptionally low-viral load, Australian-based fetal bovine serum (FBS) that is consistent, traceable to an exclusive source, characterized and provides stable supply and pricing. Nucleus Biologics partners with Australian Agricultural Company (AACo) as its exclusive source in Australia. AACo is the largest cattle company in Australia with over 16 million acres of land under its control. Numerous Nucleus Biologics product offerings are planned throughout 2017. Visit us on Facebook, LinkedIn, Twitter, and at nucleusbiologics.com. Call us at 858.251.2010.


Media Contact:
Bonnie Shaw
Clearpoint Agency

Latest Posts